The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects.
The effect of a potent inhibitor of angiotensin-converting enzyme, ramipril, was studied on both inhaled histamine and bradykinin-induced bronchoconstriction in six male, normotensive, mild asthmatic subjects. Oral administration of 10 mg ramipril caused no change in lung function or airway reactivity to inhaled histamine or bradykinin despite achieving adequate reduction in angiotensin-converting enzyme activity.
D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D001920:Bradykinin; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents; D004311:Double-Blind Method; D006632:Histamine; D006801:Humans; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D017257:Ramipril; D011897:Random Allocation
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D001993:Bronchodilator Agents; D006632:Histamine; D007703:Peptidyl-Dipeptidase A; D017257:Ramipril; D001920:Bradykinin